New hope for lung cancer patients too frail for standard chemo
NCT ID NCT07392658
Summary
This study is testing whether combining the targeted drug amivantamab with a single chemotherapy drug can help control advanced lung cancer in patients who have a specific genetic mutation and cannot tolerate standard platinum-based chemotherapy. The trial will enroll 33 adults with metastatic non-small cell lung cancer who have never had systemic treatment. Researchers will measure how well the combination shrinks tumors, delays cancer growth, and extends survival while monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
I.F.O. Istituti Fisioterapici Ospitalieri Istituto Nazionale Tumori "Regina Elena", Medical Oncology 2
RECRUITINGRoma, Roma (RM), 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.